#NEWS: Results from SYNCHRONIZE-CVOT, our Phase III cardiovascular safety study in people with obesity and CVD, CKD, and/or related risk factors, were presented today at #ScientificSessions26.
Read more: https://t.co/KguIzapMOS
#NEWS: We’re advancing Phase III trials aimed at improving outcomes for hard-to-treat cancers, including trials for a DLL3/CD3 T-cell engager in SCLC and epNEC, and another for a targeted therapy in resectable HER2-mutant NSCLC after surgery. Learn more: https://t.co/nM2zpzJuBU
#NEWS Positive data from two Phase III SYNCHRONIZE obesity trials presented at #ADA2026.
Read more about our novel glucagon/GLP-1 dual agonist and its potential to support improved metabolic health in people with obesity: https://t.co/KtgiTWcOTI
#NEWS: New data in NSCLC, SCLC, and extrapulmonary neuroendocrine carcinomas will be presented at #ASCO26, contributing to ongoing research into targeted approaches for difficult‑to‑treat cancers. Learn more: https://t.co/oNjVHWA0du
#LifeForward#Oncology
#NEWS: Our Phase III trial in people living with #obesity or overweight without type 2 diabetes has met its co-primary endpoints. Obesity is a chronic metabolic disease that can increase a person's risk for other serious health conditions.
Read more: https://t.co/YImAGHNc8a
#NEWS: Study results in @NEJM highlight meaningful progress for treatment-naïve patients with HER2-mutant advanced NSCLC. This study builds on evidence supporting personalized care for those living with cancer.
Learn more: https://t.co/GLWbIEYbaa
#LifeForward#NSCLC
#NEWS: Our targeted therapy for patients with HER2 (ERBB2)-mutant advanced NSCLC has been recommended as an initial treatment in the @NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).
Learn more: https://t.co/HoRZBif2n9
#LifeForward
#NEWS: The @US_FDA approved our orally administered treatment for patients with HER2 (ERBB2)-mutant advanced NSCLC as an initial treatment option – the first approved targeted therapy for this use.
Learn more: https://t.co/nVRTnWE7Fp
#LungCancer#LifeForward
#NEWS: Detect the SOS, a public health mission urging adults with high blood pressure or type 2 diabetes to prioritize uACR screening to help uncover hidden kidney & heart risk, launches Feb. 8 during the Big Game. Learn more: https://t.co/115r6L6r4X
#NEWS: Our treatment for adult patients with progressive pulmonary fibrosis (PPF) has been approved by the U.S. FDA. Learn more: https://t.co/4PDXPQWamq
#NEWS: Our targeted therapy for HER2-mutant advanced non-small cell lung cancer has received a Commissioner’s National Priority Voucher from the U.S. FDA.
Learn more: https://t.co/vgHVJNqc5c
#LifeForward#Oncology
This #LCAM, we’re focused on what matters most, patients and caregivers affected by cancer. We're committed to developing treatments that can make a difference.
Learn more: https://t.co/xJQRk1KmmW
#LungCancerAwarenessMonth#LifeForward
Knowing about #LungCancer is important because every year, more than 260,000 people hear the words, "You have lung cancer." Give the facts your attention this Lung Cancer Awareness Month. https://t.co/4zkbbijioQ #facts#LCAM
We’re proud to honor @BoehringerUS with the 2025 GO2 Excellence Award in Advancing Innovative Precision Medicine at our 20th annual Simply the Best Gala.
Thank you for your leadership, innovation, and commitment to patients with #LungCancer.
🔗 https://t.co/MNnrnmOeGE
Living with cancer, the small, positive moments often have the biggest impact.
We're here to celebrate these 'Big Little Things': small victories, time with loved ones, and everyday joys.
Discover how these moments make a difference: https://t.co/Pk7uHYJ3wR
#LifeForward
#NEWS: New data for HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) at #ESMO25.
These advancements represent the potential for meaningful moments for this community.
Learn more: https://t.co/GY7vaQ2U0D
#LifeForward#Oncology
#NEWS: We look forward to presenting 10 abstracts from our oncology portfolio at #ESMO25, highlighting our innovative solutions to make a significant impact on hard-to-treat cancers.
Learn more: https://t.co/3eUQq8Vqzz.
#LifeForward#Oncology
#NEWS: Our treatment for adult patients with idiopathic pulmonary fibrosis (IPF) has been approved by the U.S. FDA. Learn more: https://t.co/PEhTYh28sY
We are shaping the future of cancer care by following the science where it leads, allowing us to make significant impact in areas with the greatest unmet need.
Learn more from @STATNews: https://t.co/WAPVMWACZ1
#LifeForward#Oncology#CancerInnovation#STATNews
#NEWS: New data available in HER2 (ERBB2)-mutant advanced NSCLC in patients with stable, asymptomatic or active brain metastases – reinforcing our commitment to addressing patients’ greatest needs.
Learn more about our presentation at #WCLC25: https://t.co/9p2NwhFtxa